# Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy

> **NCT03887442** · PHASE2 · TERMINATED · sponsor: **Grupo Español de Tratamiento de Tumores de Cabeza y Cuello** · enrollment: 17 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Cetuximab + Paclitaxel

## Key facts

- **NCT ID:** NCT03887442
- **Lead sponsor:** Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-02-16
- **Primary completion:** 2012-10-02
- **Final completion:** 2012-10-02
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** low recruitment rate
- **Last updated:** 2021-01-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03887442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03887442, "Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03887442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*